ストックスクリーナーアプリを入手
23.72
3.41%
-0.8376
前日終値:
$24.56
開ける：
$24
24時間の取引高:
761.12K
Relative Volume:
0.50
時価総額：
$2.45B
収益：
$164.01M
当期純損益:
$-65.04M
株価収益率:
-34.53
EPS:
-0.687
ネットキャッシュフロー:
$-383.84M
1週間 パフォーマンス:
+1.08%
1か月 パフォーマンス:
-2.66%
6か月 パフォーマンス:
-21.34%
1年 パフォーマンス:
-15.88%
1日の値動き範囲:
$23.24
$24.14
1週間の範囲:
$23.50
$25.29
52週間の値動き範囲:
$20.23
$38.26
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, MRNA, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
23.72 | 2.45B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
526.35 | 133.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
809.32 | 83.32B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
203.04 | 81.06B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
878.00 | 55.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.00 | 42.65B | 5.76B | 514.49M | 1.10B | 4.4813 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-10-09 | 開始されました | Jefferies | Buy |
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Beam Therapeutics CEO John Evans sells $1.19m in company stock - Investing.com
Form 4 Beam Therapeutics Inc: John M. Evans (Director, CEO) For: 15 October - Investing.com Nigeria
After $1.03 option exercises, Beam Therapeutics (BEAM) CEO sells 50,000 shares under a trading plan. - Stock Titan
After a $589K sale, John M. Evans proposes selling 25,000 Beam Therapeutics (BEAM) shares. - Stock Titan
A 25,000-share sale is planned by Beam Therapeutics (BEAM) officer and director John M. Evans. - Stock Titan
Beam Therapeutics SVP Bethany Cavanagh Sells 187 Shares to Cover RSU Tax Withholding - Kalkine Media
To cover taxes, Beam Therapeutics (BEAM) treasurer sells 187 shares automatically. - Stock Titan
Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates - kalkine.ca
Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly. - Stock Titan
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Clinical Trial Progress Might Change The Case For Investing In Beam Therapeutics Stock (BEAM) - webull.com
Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View - Seeking Alpha
Beam Therapeutics faces securities fraud probe after clinical trial safety concerns cause stock to drop 9.5%. - Pluang
Beam Therapeutics (BEAM) Restored AAT Levels. Can BEAM-302 Deliver Clinical Benefit? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc.BEAM - PR Newswire
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-09-10 - Seeking Alpha
Beam Therapeutics Inc. (BEAM) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
Beam Therapeutics at cantor conference: base editing lead comes into focus - Investing.com Canada
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics - Investing.com
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com India
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com Canada
Beam Therapeutics at Citi summit: platform gains momentum across pipeline By Investing.com - Investing.com UK
Transcript : Beam Therapeutics Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 01 - marketscreener.com
Why (BEAM) Price Action Is Critical for Tactical Trading - Stock Traders Daily
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $35 to $80 - Moomoo
BEAM Reiterated by Wedbush -- Price Target Maintained at $65 - GuruFocus
Beam Therapeutics (NasdaqGS:BEAM) Stock Forecast & Analyst Predictions - Simply Wall Street
BofA Securities Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $43 - Moomoo
BEAM Looks 14.6% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com India
Beam Therapeutics at Wells Fargo conference: base editing gains ground By Investing.com - Investing.com UK
Beam drops after updating Phase 1/2 trial data for gene-editing drug - Seeking Alpha
3 Promising Genomics Stocks in the Spotlight in 2026 - TradingView
BEAM - Finviz
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment - Yahoo Finance
Beam Therapeutics reports BEAM-302 AATD trial update - grafa.com
BEAM Looks 26.9% Overvalued on GF Value™ - GuruFocus
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 - manilatimes.net
Beam Therapeutics Presents Updated Clinical Data from the - GlobeNewswire
Beam Therapeutics (BEAM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga España
BEAM Stock Price and Chart — NASDAQ:BEAM - TradingView
BEAM Should I Buy - Intellectia AI
Beam Therapeutics appoints Eric Foster as CCO - The Pharma Letter
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Nigeria
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com South Africa
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com - Investing.com Canada
Beam Therapeutics names Eric Foster as chief commercial officer - Investing.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Barchart.com
Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer - Stock Titan
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences - news.futunn.com
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
Beam Therapeutics Inc (BEAM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| JOHN M EVANS | Officer |
Oct 16 '26 |
Proposed Sale |
23.98 |
25,000 |
599,595 |
0 |
| Evans John M. | CEO |
Oct 16 '26 |
Sale |
23.98 |
25,000 |
599,595 |
1,047,205 |
| Evans John M. | CEO |
Oct 16 '26 |
Option Exercise |
1.03 |
25,000 |
25,750 |
1,072,205 |
| JOHN M EVANS | Officer |
Oct 15 '26 |
Proposed Sale |
23.57 |
25,000 |
589,150 |
0 |
| Evans John M. | CEO |
Oct 15 '26 |
Sale |
23.57 |
25,000 |
589,150 |
1,047,205 |
| Cavanagh Bethany J | SVP, Finance and Treasurer |
Oct 01 '26 |
Sale |
24.41 |
187 |
4,565 |
50,984 |
| Simon Amy | Chief Medical Officer |
Jul 27 '26 |
Sale |
25.74 |
16,667 |
429,037 |
85,696 |
| AMY SIMON | Officer |
Jul 27 '26 |
Proposed Sale |
25.74 |
16,677 |
429,294 |
0 |
| Evans John M. | CEO |
Jun 30 '26 |
Sale |
34.31 |
25,000 |
857,685 |
1,047,205 |
| JOHN M EVANS | Officer |
Jun 30 '26 |
Proposed Sale |
34.31 |
25,000 |
857,685 |
0 |
1.87%
0.00%
大文字化:
|
ボリューム (24 時間):